Docoh
Loading...

PVCT Provectus Biopharmaceuticals

Provectus Biopharmaceuticals, Inc. is a development stage biopharmaceutical company. It engages in the development of ethical pharmaceuticals for oncology and dermatology indications. Its prescription drugs treats several life threatening cancers including metastatic melanoma, liver cancer, and breast cancer. The company was founded by Eric A. Wachter in 2002 and is headquartered in Knoxville, TN.

Company profile

Ticker
PVCT
Exchange
CEO
Bruce Horowitz
Employees
Incorporated
Location
Fiscal year end
Former names
PROVECTUS PHARMACEUTICAL INC, PROVECTUS PHARMACEUTICALS INC, SPM GROUP INC, ZAMAGE DIGITAL IMAGING INC
SEC CIK
IRS number
900031917

PVCT stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

2 Mar 21
21 Apr 21
31 Dec 21
Quarter (USD)
Dec 20 Sep 20 Jun 20 Mar 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 97.23K 97.23K 97.23K 97.23K 97.23K 97.23K
Cash burn (monthly) 296.43K 41.12K 400.87K 413.63K 319.19K 340.48K
Cash used (since last report) 1.1M 152.3K 1.48M 1.53M 1.18M 1.26M
Cash remaining -1M -55.07K -1.39M -1.43M -1.08M -1.16M
Runway (months of cash) -3.4 -1.3 -3.5 -3.5 -3.4 -3.4

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
10 Nov 20 Bruce Horowitz Common Stock Grant Aquire A No No 0 800,000 0 2,227,243
10 Nov 20 Bruce Horowitz Stock Options Comon Stock Grant Aquire A No No 0.12 2,425,000 291K 2,425,000
10 Nov 20 John Lacy III Common Stock Grant Aquire A No No 0 100,000 0 200,000
10 Nov 20 John Lacy III Stock Options Common Stock Grant Aquire A No No 0.2862 100,000 28.62K 100,000
10 Nov 20 Heather Raines Common Stock Grant Aquire A No No 0 50,000 0 1,213,153

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

13F holders
Current Prev Q Change
Total holders 0 0
Opened positions 0 0
Closed positions 0 0
Increased positions 0 0
Reduced positions 0 0
13F shares
Current Prev Q Change
Total value 0 0
Total shares 0 0
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
Largest transactions
Shares Bought/sold Change

Financial report summary

?
Competition
Webster Bailey
Management Discussion
  • Total operating expenses were $4,963,576 for the year ended December 31, 2020, a decrease of $1,336,120 or 21.2% compared to the year ended December 31, 2019. The decrease was driven by our continued transformation and process improvement efforts within the Company, along with slower recruitment and treatment in clinical trials due to the effects of SARS-CoV-2. Net loss for the year ended December 31, 2020 was $6,677,587, a decrease of $244,950 or 3.5% compared to the year ended December 31, 2019, which resulted from costs incurred in connection with our preclinical and clinical trial programs and general and administrative costs.
  • Research and development expenses were $2,812,760 for the year ended December 31, 2020, a decrease of $1,189,254 or 29.7% compared to the year ended December 31, 2019. The decrease was due to (i) lower clinical operations due to closure of Phase III study in early 2019 and slower recruitment and treatment in clinical trials due to the effects of SARS-CoV-2, (ii) lower amortization due to patents being fully amortized, and (iii) lower payroll and related taxes due to a lower negotiated employment agreement.
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg
New words: AACR, abstract, actinic, addressed, AFCO, affordable, aim, AOCL, API, area, Aru, attract, bacteria, bacterial, Bailey, behavior, Biochemistry, Biology, Black, Calgary, Canada, canceled, CB, certiorari, cGMP, chaperone, clarification, College, compelling, composition, contact, contributor, cornea, CoV, Cumming, curative, deepened, deferral, Department, depository, disagreement, disbursement, DP, ePoster, forgivable, forgiven, frequency, Gallery, gel, gemcitabine, headcount, heat, HX, HXs, immunomodulatory, immunotherapeutic, Indian, industry, intranasal, Japan, Jonathan, Kurosu, landmark, launched, leadership, Lee, legacy, lending, mCRC, MDR, Michio, microbiology, mutant, naive, Narendran, neck, NOL, Oak, oncologist, online, ophthalmology, opposition, pandemic, pari, permission, Pfizer, Pharmacy, Physiology, platform, PO, PPP, precautionary, Premium, prerequisite, Professor, prolonged, pronouncement, prophylactic, proprietarily, PRRT, QbD, RBD, referencing, refining, regaining, repair, reportedly, respiratory, revealed, Ridge, School, Seattle, shipped, shock, SIR, SITC, spectrum, spot, STING, stored, strain, Supreme, surpassed, symbol, syndrome, temperature, temporary, terminology, TGA, top, underscored, unforgiven, uploaded, UTHSC, vacant, viable, virology, Virtual, Webster, workforce, workplace, World, writ
Removed: advisory, al, Alexandra, applicability, asin, assessed, BDO, began, biomarker, breadth, Brisbane, capability, capable, cellular, characterize, Chicago, Children, choice, classify, Clinic, colon, Consortium, consultant, contrast, demonstrated, dendritic, denying, discovered, downregulation, effector, employed, England, evaluated, Experimental, exploratory, focused, functioning, Hospital, hydrogel, identify, image, imaging, immunogenic, immunologic, induce, inhibition, injected, Kettering, killer, led, lieu, listed, Liu, locally, London, low, lung, mediated, Memorial, metastasized, mild, moderate, natural, opened, ovarian, participating, pivotal, POETIC, primer, profiling, Qin, radiologic, radiotherapy, showing, signaling, Sloan, synergy, Toomey, underway, unique, USA, viral, widely, yielding